PET scan study in pulmonary hypertension related to scleroderma
Part of Heart & circulation, Lungs & breathing clinical trials.
This early study uses a PET scan (a type of imaging test) to better understand lung blood-vessel disease in people who have pulmonary hypertension related to scleroderma. It may help researchers find how imaging signals relate to disease and risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have confirmed pulmonary hypertension linked to scleroderma (from a right-heart catheter test), based on the study’s specific definitions
- You do not smoke
- You can understand the consent form and follow study instructions
- You are not pregnant or breastfeeding
- You can lie still for a long period and you are not claustrophobic
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
This study looks at tiny particles in your blood to see if they can predict whether you might develop a serious lung condition called pulmonary arterial hypertension (high blood pressure in the lungs). It aims to find better ways to detect and manage this complication early.
This trial uses a special imaging technique (xenon MRI) to see how well the lungs are functioning in people with pulmonary arterial hypertension (PAH) who are being treated with the drug sotatercept. It aims to understand if the drug improves lung function.
This trial uses a special PET/MRI scan to look for early signs of lung scarring and inflammation using a “collagen-targeting” tracer. It may help doctors better identify early interstitial lung disease (IL D) and track it over time.
This study uses a special PET scan tracer (XBD173) to look at inflammation in the lungs of people with pulmonary arterial hypertension (PAH). It aims to understand the role of a protein called TSPO in PAH and may help guide future treatments.
This study tests a special PET scan that uses a new tracer to help see fibrosis (scarring) in the body. It may help doctors better understand and manage conditions like lung or liver fibrosis.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.